After successful inhibition of LRRK2 activity by small molecular inhibitors that resulted in decelerated α-syn aggregation and neurodegeneration in animal models (Daher et al. 2015; Daher et al. 2014), two LRRK2 kinase inhibitors known as DNL201 and DNL151 have been introduced for administration to both healthy volunteers and patients with PD in clinical trials. The gene discussed is LRRK2; the disease is Parkinson disease.